12 results on '"Dwyer, Jamie P."'
Search Results
2. Contributors
- Author
-
Adler, Sharon, primary, Adrogué, Horacio J., additional, Aiyagari, Venkatesh, additional, Alpern, Robert J., additional, Alpers, Charles E., additional, Appel, Gerald B., additional, Arogundade, Fatiu A., additional, Ash, Stephen R., additional, Asif, Arif, additional, Aucouturier, Pierre, additional, August, Phyllis, additional, Bakris, George L., additional, Barlow, Adam D., additional, Barsoum, Rashad S., additional, Baylis, Chris, additional, Bello, Aminu, additional, Berl, Tomas, additional, Bhat, Suresh, additional, Bircher, Gemma, additional, Bonventre, Joseph V., additional, Bouchard, Josée, additional, Brook, Nicholas R., additional, Brown, Christopher, additional, Brown, Mark A., additional, Burdmann, Emmanuel A., additional, Bushinsky, David A., additional, Cattran, Daniel C., additional, Cervelli, Matthew J., additional, Chadban, Steven J., additional, Charlton, Karen E., additional, Chen, Yipu, additional, Cheng, Ignatius K.P., additional, Connolly, John O., additional, Couser, William G., additional, Cravedi, Paolo, additional, D’Agati, Vivette D., additional, Danovitch, Gabriel M., additional, Davies, Simon J., additional, Davison, John M., additional, Derman, Wayne, additional, DiBona, Gerald F., additional, Drüeke, Tilman B., additional, Dwyer, Jamie P., additional, Eckardt, Kai-Uwe, additional, Eckel, Jason, additional, Eitner, Frank, additional, Kossi, Mohsen El, additional, Elger, Marlies, additional, Elhassan, Elwaleed A., additional, Evenepoel, Pieter, additional, Fabian, June, additional, Falk, Ronald J., additional, Feehally, John, additional, Fischer, Evelyne A., additional, Fisher, Jonathan S., additional, Floege, Jürgen, additional, Fogazzi, Giovanni B., additional, Foreman, John W., additional, Fujita, Toshiro, additional, Gennari, F. John, additional, Gkougkousis, Evangelos G., additional, Glassock, Richard J., additional, Gorelick, Philip B., additional, Greco, Barbara A., additional, Gross, Peter, additional, Guay-Woodford, Lisa M., additional, Haddad, Nabil, additional, Harris, Kevin P.G., additional, Harris, Peter C., additional, Hebert, Lee A., additional, Heduschka, Peter, additional, Herzog, Charles A., additional, Hooton, Thomas, additional, Hörl, Walter H., additional, Hoyer, Peter F., additional, Hughes, Jeremy, additional, Hugo, Christian, additional, Imai, Enyu, additional, Irish, Ashley B., additional, Jaber, Bertrand L., additional, Jain, Sunjay, additional, Jayne, David, additional, Jefferson, J. Ashley, additional, Jennette, J. Charles, additional, Jha, Vivekanand, additional, Johnson, Richard J., additional, Kanagasundaram, Nigel S., additional, Kanellis, John, additional, Karumanchi, S. Ananth, additional, Kashtan, Clifford E., additional, Kauffman, Carol A., additional, Kawar, Bisher, additional, Kestenbaum, Bryan, additional, Ketteler, Markus, additional, Kopp, Jeffrey, additional, Kotanko, Peter, additional, Kriz, Wilhelm, additional, Kuhlmann, Martin K., additional, Kuypers, Dirk R., additional, Lakey, Jonathan R.T., additional, Lambert, Estelle V., additional, Lawton, William, additional, Levey, Andrew S., additional, Levin, Nathan W., additional, Levy, Jeremy, additional, Lewington, Andrew, additional, Lewis, Julia B., additional, Li, Felix F.K., additional, Linas, Stuart L., additional, Luft, Friedrich C., additional, Maaten, Jan C. ter, additional, Macdougall, Iain C., additional, Macedo, Etienne, additional, Madias, Nicolaos E., additional, Magee, Colm C., additional, Marsh, Christopher L., additional, Marshall, Mark R., additional, Martin, Kevin J., additional, Mason, Philip D., additional, Mathews, Ranjiv, additional, Mattoo, Tej K., additional, Mehta, Ravindra L., additional, Meier-Kriesche, Herwig-Ulf, additional, Mellon, J. Kilian, additional, Mirbolooki, M. Reza, additional, Monk, Rebeca D., additional, Moulin, Bruno, additional, Mulley, William R., additional, Nahas, Meguid El, additional, Naicker, Saraladevi, additional, Nangaku, Masaomi, additional, Neild, Guy H., additional, Nicholls, M. Gary, additional, Nicholson, Michael L., additional, O’Connell, Philip J., additional, O’Neill, W. Charles, additional, Palmer, Biff F., additional, Parikh, Chirag, additional, Pham, Phuong-Chi T., additional, Pham, Phuong-Thu T., additional, Pham, Son V., additional, Phelps, Richard G., additional, Pichler, Raimund, additional, Podymow, Tiina, additional, Pommer, Wolfgang, additional, Pusey, Charles D., additional, Rabb, Hamid, additional, Rayner, Brian, additional, Rayner, Hugh C., additional, Remuzzi, Giuseppe, additional, Richards, A. Mark, additional, Rippe, Bengt, additional, Ritz, Eberhard, additional, Robertson, R. Paul, additional, Rodriguez-Iturbe, Bernardo, additional, Ronco, Claudio, additional, Ronco, Pierre M., additional, Ross, Edward A., additional, Rossert, Jerome A., additional, Ruggenenti, Piero, additional, Ruland, Sean, additional, Russ, Graeme R., additional, Samuels, Martin A., additional, Sarafidis, Pantelis A., additional, Schena, F. Paolo, additional, Schold, Jesse D., additional, Schrier, Robert W., additional, Seabra, Victor F., additional, Segal, Mark S., additional, Seifter, Julian Lawrence, additional, Shastri, Shani, additional, Shirley, David G., additional, Sitprija, Visith, additional, Srinivas, Titte R., additional, Stenvinkel, Peter, additional, Stevens, Lesley A., additional, Textor, Stephen C., additional, Thurman, Joshua M., additional, Tong, Li-Li, additional, Topham, Peter S., additional, Tordoir, Jan H.M., additional, Torres, Vicente E., additional, Trence, Dace, additional, Turner, A. Neil, additional, Unwin, Robert J., additional, Vacher-Coponat, Henri, additional, Visweswaran, R. Kasi, additional, Wasse, Haimanot, additional, Wavamunno, Moses D., additional, Weiner, I. David, additional, Wheeler, David C., additional, Williams, Bryan, additional, Williams, John D., additional, Wingo, Charles S., additional, Winn, Michelle, additional, Wiseman, Alexander C., additional, Wolf, Gunter, additional, Womer, Karl, additional, Woodrow, Graham, additional, Wymer, David C., additional, Yang, Li, additional, and Yu, Xueqing, additional
- Published
- 2010
- Full Text
- View/download PDF
3. Thromboembolic Renovascular Disease
- Author
-
Greco, Barbara A., primary, Dwyer, Jamie P., additional, and Lewis, Julia B., additional
- Published
- 2010
- Full Text
- View/download PDF
4. Lead Authors and Contributors
- Author
-
Benjamin, Ivor J., primary, Tariq, Sara G., additional, Beland, Susan S., additional, Benjamin, Ivor J., additional, Bull, David, additional, Hamdan, Mohamed H., additional, Li, Dean Y., additional, Litwin, Sheldon E., additional, Michaels, Andrew D., additional, Morshedzadeh, Jack H., additional, Stehlik, Josef, additional, Whitehead, Kevin J., additional, Victor, Ronald G., additional, Vongpatanasin, Wanpen, additional, Rounds, Sharon I., additional, Aliotta, Jason M., additional, Casserly, Brian, additional, Jankowich, Matthew D., additional, McCool, F. Dennis, additional, Eagle, Kim A., additional, Lau, Wei C., additional, Harris, Raymond C., additional, Andreoli, Thomas E., additional, Basford, Amanda W., additional, Cavanaugh, Kerri L., additional, Dwyer, Jamie P., additional, Golper, Thomas A., additional, Krause, Michelle W., additional, Ikizler, T. Alp, additional, Lewis, Julia B., additional, Luther, James M., additional, Pirkle, James L., additional, Portilla, Didier, additional, Safirstein, Robert L., additional, Schulman, Gerald, additional, Shah, Sudhir V., additional, Zent, Roy, additional, Wolfe, M. Michael, additional, Blanton, Wanda P., additional, Bliss, Charles M., additional, Farraye, Francis A., additional, Huang, Christopher S., additional, Jacobson, Brian C., additional, Lichtenstein, David R., additional, Lowe, Robert, additional, Mishkin, Daniel S., additional, Moore, T. Carlton, additional, Oviedo, Jaime A., additional, Pedrosa, Marcos C., additional, Schimmel, Elihu M., additional, Schroy, Paul C., additional, Singh, Satish K., additional, Tseng, Chi-Chuan, additional, Fallon, Michael B., additional, Arguedas, Miguel R., additional, Garcia-Gallont, Rudolf, additional, Kochar, Rajan, additional, McGuire, Brendan M., additional, Mönkemüller, Klaus, additional, Neumann, Helmut, additional, M. Sheikh, Aasim, additional, Varadarajulu, Shyam, additional, Berliner, Nancy, additional, Lacy, Jill, additional, S. Rinder, Christine, additional, M. Rinder, Henry, additional, G. Rose, Michal, additional, E. Seropian, Stuart, additional, Tormey, Christopher, additional, Torres, Richard, additional, Wang, Eunice S., additional, Griggs, Jennifer J., additional, Burtness, Barbara A., additional, Khorana, Alok A., additional, Lantz, Paula M., additional, Todd, Robert F., additional, Smith, Robert J., additional, Brooks, David G., additional, Gopalakrishnan, Geetha, additional, Hamdy, Osama, additional, Warren, Michelle P., additional, Ziegler, Thomas R., additional, Braunstein, Glenn D., additional, Barnett, Philip S., additional, Herman-Bonert, Vivien S., additional, Friedman, Theodore C., additional, Charney, Pamela A., additional, Carney, Patricia I., additional, Ehrenthal, Deborah B., additional, Kottenhahn, Renee K., additional, Smith, Joseph A., additional, Milam, Douglas F., additional, Starkman, Johnathan S., additional, Stewart, Andrew F., additional, Greenspan, Susan L., additional, Hodak, Steven P., additional, Horwitz, Mara J., additional, LeBeau, Shane O., additional, Roodman, G. David, additional, Moreland, Larry W., additional, Agarwal, Surabhi, additional, Ascherman, Dana P., additional, Domsic, Robyn T., additional, Elliott, Jennifer Rae, additional, Kao, Amy H., additional, Koumpouras, Fotios, additional, Kwoh, C. Kent, additional, Lienesch, Douglas W., additional, McKinnon-Maksimowicz, Kathleen, additional, Medsger, Thomas A., additional, Mohan, Niveditha, additional, Wing, Edward J., additional, Armitage, Keith B., additional, Beckwith, Curt G., additional, Bobak, David A., additional, Fairley, Jessica K., additional, Fulton, Scott A., additional, Hileman, Corrilynn O., additional, Lange, Christoph, additional, Lederman, Michael M., additional, Lemonovich, Tracy L., additional, Lisagaris, Michelle V., additional, Ray, Amy J., additional, Rodriguez, Benigno, additional, Salata, Robert A., additional, Watkins, Richard R., additional, Bradsher, Robert W., additional, Griggs, Robert C., additional, Berg, Michel J., additional, Ciafaloni, Emma, additional, Counihan, Timothy J., additional, Cheshire, William P., additional, de los Reyes, Emily C., additional, Jackson, Carlayne E., additional, Kerber, Kevin A., additional, Liu, Lynn C., additional, Ling, Geoffrey S.F., additional, Lyness, Jeffery M., additional, Lynn, Deborah Joanne, additional, Marshall, Frederick J., additional, McCarthy, Allan, additional, Murphy, Sinéad M., additional, Nath, Avindra, additional, Roach, E. Steve, additional, Rogers, Lisa R., additional, Simon, Roger P., additional, Cohen, Harvey J., additional, Heflin, Mitchell T., additional, Quill, Timothy E., additional, Holloway, Robert G., additional, Hillis, L. David, additional, and Lange, Richard A., additional
- Published
- 2010
- Full Text
- View/download PDF
5. A risk-based monitoring approach to source data monitoring and documenting monitoring findings.
- Author
-
Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, and VanBuren JM
- Subjects
- Humans, Clinical Trials as Topic methods, Risk Assessment methods, Clinical Trials Data Monitoring Committees organization & administration, Research Design
- Abstract
Background: Clinical trial monitoring is evolving from labor-intensive to targeted approaches. The traditional 100% Source Data Monitoring (SDM) approach fails to prioritize data by significance, diverting attention from critical elements. Despite regulatory guidance on Risk-Based Monitoring (RBM), its widespread implementation has been slow., Methods: Our study teams assess the study's overall risk, document heightened and critical risks, and create a study-specific risk-based monitoring plan, integrating SDM and Central Data Monitoring (CDM). SDM combines a fixed list of pre-identified variables and a list of randomly identified variables to monitor. Identifying variables follows a two-step approach: first, a random sample of participants is selected, second, a random set of variables for each participant selected is identified. Sampling weights prioritize critical variables. Regular team meetings are held to discuss and compile significant findings into a Study Monitoring Report., Results: We present a random SDM sample and a Study Monitoring Report. The random SDM output includes a look-up table for selected database elements. The report provides a holistic view of the study issues and overall health., Conclusions: The proposed random sampling method is used to monitor a representative set of critical variables, while the Study Monitoring Report is written to summarize significant monitoring findings and data trends. The report allows the sponsor to assess the current status of the study and data effectively. Communicating and sharing emerging insights facilitates timely adjustments of future monitoring activities, optimizing efficiencies, and study outcomes., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
6. Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record.
- Author
-
Chu CD, Lenoir KM, Rai NK, Soman S, Dwyer JP, Rocco MV, Agarwal AK, Beddhu S, Powell JR, Suarez MM, Lash JP, McWilliams A, Whelton PK, Drawz PE, Pajewski NM, Ishani A, and Tuot DS
- Subjects
- Aged, Female, Humans, Male, Antihypertensive Agents therapeutic use, Blood Pressure, Electronic Health Records, Treatment Outcome, Acute Coronary Syndrome complications, Cardiovascular Diseases epidemiology, Heart Failure drug therapy, Hypertension diagnosis, Hypertension epidemiology, Hypertension complications, Myocardial Infarction epidemiology, Stroke epidemiology
- Abstract
Background: Randomized trials are the gold standard for generating clinical practice evidence, but follow-up and outcome ascertainment are resource-intensive. Electronic health record (EHR) data from routine care can be a cost-effective means of follow-up, but concordance with trial-ascertained outcomes is less well-studied., Methods: We linked EHR and trial data for participants of the Systolic Blood Pressure Intervention Trial (SPRINT), a randomized trial comparing intensive and standard blood pressure targets. Among participants with available EHR data concurrent to trial-ascertained outcomes, we calculated sensitivity, specificity, positive predictive value, and negative predictive value for EHR-recorded cardiovascular disease (CVD) events, using the gold standard of SPRINT-adjudicated outcomes (myocardial infarction (MI)/acute coronary syndrome (ACS), heart failure, stroke, and composite CVD events). We additionally compared the incidence of non-CVD adverse events (hyponatremia, hypernatremia, hypokalemia, hyperkalemia, bradycardia, and hypotension) in trial versus EHR data., Results: 2468 SPRINT participants were included (mean age 68 (SD 9) years; 26% female). EHR data demonstrated ≥80% sensitivity and specificity, and ≥ 99% negative predictive value for MI/ACS, heart failure, stroke, and composite CVD events. Positive predictive value ranged from 26% (95% CI; 16%, 38%) for heart failure to 52% (95% CI; 37%, 67%) for MI/ACS. EHR data uniformly identified more non-CVD adverse events and higher incidence rates compared with trial ascertainment., Conclusions: These results support a role for EHR data collection in clinical trials, particularly for capturing laboratory-based adverse events. EHR data may be an efficient source for CVD outcome ascertainment, though there is clear benefit from adjudication to avoid false positives., Competing Interests: Declaration of Competing Interest CDC receives research support from Bayer Healthcare, Inc. outside the submitted work. AM reports ownership interest in iEnroll, LLC. The remaining authors have nothing to disclose., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
- Author
-
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, and Wheeler DC
- Subjects
- Adult, Benzhydryl Compounds adverse effects, Glomerular Filtration Rate, Glucosides, Humans, Incidence, Kidney, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic epidemiology, Sodium-Glucose Transporter 2 Inhibitors adverse effects
- Abstract
This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on having chronic kidney disease (CKD) and substantial albuminuria. DAPA-CKD was a randomized, double-blind, placebo-controlled trial that had a median follow-up of 2.4 years. Adults with CKD (urinary albumin-to-creatinine ratio 200-5000 mg/g and estimated glomerular filtration rate 25-75 mL/min/1.73m
2 ) were randomized to dapagliflozin 10 mg/day matched to placebo (2152 individuals each). An abrupt decline in kidney function was defined as a pre-specified endpoint of doubling of serum creatinine between two subsequent study visits. We also assessed a post-hoc analysis of investigator-reported acute kidney injury-related serious adverse events. Doubling of serum creatinine between two subsequent visits (median time-interval 100 days) occurred in 63 (2.9%) and 91 (4.2%) participants in the dapagliflozin and placebo groups, respectively (hazard ratio 0.68 [95% confidence interval 0.49, 0.94]). Accounting for the competing risk of mortality did not alter our findings. There was no heterogeneity in the effect of dapagliflozin on abrupt declines in kidney function based on baseline subgroups. Acute kidney injury-related serious adverse events were not significantly different and occurred in 52 (2.5%) and 69 (3.2%) participants in the dapagliflozin and placebo groups, respectively (0.77 [0.54, 1.10]). Thus, in patients with CKD and substantial albuminuria, dapagliflozin reduced the risk of abrupt declines in kidney function., (Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
8. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
- Author
-
Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, and Wiviott SD
- Subjects
- Aged, Atherosclerosis complications, Atherosclerosis drug therapy, Body Weight drug effects, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 prevention & control, Double-Blind Method, Female, Glycated Hemoglobin analysis, Humans, Male, Middle Aged, Overweight complications, Prediabetic State complications, Prediabetic State drug therapy, Prediabetic State prevention & control, Remission Induction, Weight Loss drug effects, Appetite Depressants therapeutic use, Benzazepines therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Obesity complications
- Abstract
Background: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention and remission., Methods: In this randomised, double-blind, placebo-controlled trial done in eight countries, we recruited overweight or obese patients (body-mass index ≥27 kg/m
2 ) with or at high risk for atherosclerotic vascular disease. Eligible patients were aged 40 years or older; patients at high risk for atherosclerotic vascular disease had to be aged 50 years or older with diabetes and at least one other risk factor. Patients were randomly assigned to receive either lorcaserin (10 mg twice daily) or matching placebo. Additionally, all patients had access to a standardised weight management programme based on lifestyle modification. The prespecified primary metabolic efficacy endpoint of time to incident diabetes was assessed in patients with prediabetes at baseline. The prespecified secondary outcomes for efficacy were incident diabetes in all patients without diabetes, achievement of normoglycaemia in patients with prediabetes, and change in glycated haemoglobin (HbA1c ) in patients with diabetes. Hypoglycaemia was a prespecified safety outcome. Analysis was by intention to treat, using Cox proportional hazard models for time-to-event analyses. This trial is registered with ClinicalTrials.gov, number NCT02019264., Findings: Between Feb 7, 2014, and Nov 20, 2015, 12 000 patients were randomly assigned to lorcaserin or placebo (6000 patients in each group) and followed up for a median of 3·3 years (IQR 3·0-3·5). At baseline, 6816 patients (56·8%) had diabetes, 3991 (33·3%) prediabetes, and 1193 (9·9%) normoglycaemia. At 1 year, patients treated with lorcaserin had a net weight loss beyond placebo of 2·6 kg (95% CI 2·3-2·9) for those with diabetes, 2·8 kg (2·5-3·2) for those with prediabetes, and 3·3 kg (2·6-4·0) for those with normoglycaemia (p<0·0001 for all analyses). Lorcaserin reduced the risk of incident diabetes by 19% in patients with prediabetes (172 [8·5%] of 2015 vs 204 [10·3%] of 1976; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·038) and by 23% in patients without diabetes (174 [6·7%] of 2615 vs 215 [8·4%] of 2569; 0·77, 0·63-0·94; p=0·012). Lorcaserin resulted in a non-significant increase in the rate of achievement of normoglycaemia in patients with prediabetes (185 [9·2%] vs 151 [7·6%]; 1·20, 0·97-1·49; p=0·093). In patients with diabetes, lorcaserin resulted in a reduction of 0·33% (95% CI 0·29-0·38; p<0·0001) in HbA1c compared with placebo at 1 year from a mean baseline of 53 mmol/mol (7·0%). In patients with diabetes at baseline, severe hypoglycaemia with serious complications was rare, but more common with lorcaserin (12 [0·4%] vs four [0·1%] events; p=0·054)., Interpretation: Lorcaserin decreases risk for incident diabetes, induces remission of hyperglycaemia, and reduces the risk of microvascular complications in obese and overweight patients, supporting the role of lorcaserin as an adjunct to lifestyle modification for chronic management of weight and metabolic health., Funding: Eisai., (Copyright © 2018 Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
9. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
- Author
-
Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, and Banach M
- Subjects
- Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents adverse effects, Biomarkers blood, Clinical Trials, Phase III as Topic, Down-Regulation, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia blood, Hypercholesterolemia complications, Hypercholesterolemia diagnosis, Kidney physiopathology, Male, Middle Aged, PCSK9 Inhibitors, Proprotein Convertase 9 metabolism, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic physiopathology, Risk Factors, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Anticholesteremic Agents therapeutic use, Cholesterol, LDL blood, Hypercholesterolemia drug therapy, Renal Insufficiency, Chronic complications
- Abstract
Individuals with chronic kidney disease are at increased risk of premature cardiovascular disease. Among them, many with elevated low-density lipoprotein cholesterol (LDL-C) are unable to achieve optimal LDL-C on statins and require additional lipid-lowering therapy. To study this, we compared the LDL-C-lowering efficacy and safety of alirocumab in individuals with hypercholesterolemia with impaired renal function, defined as eGFR 30-59 ml/min/1.73 m
2 , to those without impaired renal function eGFR ≥60 ml/min/1.73 m2 . A total of 4629 hypercholesterolemic individuals without or with impaired renal function, pooled from eight phase 3 ODYSSEY trials (double-blind treatments of 24-104 weeks), were on alirocumab 150 mg or 75/150 mg every two weeks vs. placebo or ezetimibe. Overall, 10.1% had impaired renal function and over 99% were receiving statin treatment. Baseline LDL-C in alirocumab and control groups was comparable in subgroups analyzed. LDL-C reductions at week 24 ranged from 46.1 to 62.2% or 48.3 to 60.1% with alirocumab among individuals with or without impaired renal function, respectively. Similar reductions were observed for lipoprotein (a), non-high-density lipoprotein cholesterol, apolipoprotein B, and triglycerides. Safety data were similar in both treatment subgroups, regardless of the degree of CKD. Renal function did not change over time in response to alirocumab. This post hoc efficacy analysis is limited by evaluation of alirocumab treatment effects on renal and lipid parameters by serum biochemistry. Thus, alirocumab consistently lowered LDL-C regardless of impaired renal function, with safety comparable to control, among individuals with hypercholesterolemia who nearly all were on statin treatment., (Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
10. Does renal dysfunction and method of bridging support influence heart transplant graft survival?
- Author
-
Haglund NA, Feurer ID, Dwyer JP, Stulak JM, DiSalvo TG, Keebler ME, Schlendorf KH, Wigger MA, and Maltais S
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Preoperative Care methods, Retrospective Studies, Risk Factors, Severity of Illness Index, Young Adult, Cardiotonic Agents therapeutic use, Graft Survival, Heart Failure complications, Heart Failure surgery, Heart Transplantation, Heart-Assist Devices, Renal Insufficiency complications
- Abstract
Background: Renal insufficiency is common in status 1B patients supported with inotropes or a continuous flow left ventricular device (CF-LVAD) as a bridge to heart transplantation. We evaluated the association of renal function and inotrope versus CF-LVAD support on posttransplant graft survival in status 1B patients., Methods: The Scientific Registry for Transplant Recipients database was analyzed for posttransplant survival in status 1B patients bridged with inotropes or CF-LVAD who underwent transplantation between 2003 and 2012. Pretransplant renal function was measured by estimating glomerular filtration rate (GFR) and was stratified as less than 45 mL · min(-1) · 1.73 m(-2), 45 to 59, and 60 or greater. Univariate Kaplan-Meier and multivariate Cox regression models were used to evaluate the main effects of GFR strata and inotropes versus CF-LVAD, and the interaction effect of GFR strata by CF-LVAD, on graft survival., Results: This study included 4,158 status 1B patients (74% male, aged 53 ± 12 years). Of those, 659 patients had a CF-LVAD (HeartMate-II [Thoratec, Pleasanton, CA], n = 638; HVAD [HeartWare, Framingham, MA], n = 21), and 3,530 were receiving inotropes (31 CF-LVAD patients were also receiving inotropes). Kaplan-Meier analyses demonstrated reduced graft survival (p = 0.022) in patients with pretransplant GFR less than 45 versus GFR 45 to 59 (p = 0.062) and versus GFR 60 or greater (p = 0.007), and no effect of inotrope versus CF-LVAD support on graft survival (p = 0.402). Multivariate analysis demonstrated that, after adjusting for the main effects of GFR stratum, CF-LVAD, and inotropes, status 1B patients bridged with a CF-LVAD and GFR in the lowest stratum had reduced graft survival (interaction effect p = 0.040)., Conclusions: Pretransplant renal insufficiency was associated with reduced posttransplant graft survival in status 1B patients. This risk is increased for patients bridged with a CF-LVAD (versus inotropes) who have GFR in the lowest stratum., (Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
11. Vicarious contrast excretion by the gallbladder in contrast nephropathy.
- Author
-
Umana IE and Dwyer JP
- Subjects
- Aged, Contrast Media metabolism, Humans, Iodine adverse effects, Male, Tomography, Contrast Media adverse effects, Gallbladder metabolism, Kidney Diseases chemically induced
- Published
- 2009
- Full Text
- View/download PDF
12. The fluid craze.
- Author
-
Lette F and Dwyer JP
- Subjects
- Humans, Water administration & dosage, Water metabolism, Chlorides blood, Drinking, Hyponatremia etiology, Water adverse effects
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.